Latest Ñî¹óåú´«Ã½Ò•îl Health News Stories
Shutdown Halts Some Health Services as Political Risks Test Parties’ Resolve
Congressional Democrats and Republicans are at an impasse in negotiations. Which side will blink first?
Big Pharma Is Betting on Bigger Political Ambitions From Sen. Tim Scott
The South Carolina senator led the congressional pack in pharma campaign contributions for the second half of 2021. There are clear reasons.
A Ñî¹óåú´«Ã½Ò•îl Health News database tracks campaign donations from drugmakers over the past 10 years.
Pharma Campaign Cash Delivered to Key Lawmakers With Surgical Precision
With an eye to shutting down Medicare drug price negotiations, drug companies and their lobbying groups gave roughly $1.6 million in the first six months of 2021, with Democrats edging closer than they have in a decade to Republicans’ total haul.
A Senator From Arizona Emerges As A Pharma Favorite
Sen. Kyrsten Sinema has received almost $100,000 from drug companies in the current election cycle, a KHN analysis shows, one of the largest cash hauls in Congress. And it’s only her first term.
Senators Who Led Pharma-Friendly Patent Reform Also Prime Targets For Pharma Cash
Three senators on a revived subcommittee received more than $100,000 each from drugmakers.
Congress Rakes In Millions From Drugmakers
In the first six months of this year, pharmaceutical firms and their trade groups donated almost $4 million to the campaigns of a variety of senators and House members.
Pharma Cash Rolls Into Congress To Defend An Embattled Industry
Congress has a variety of reforms in mind that could roil the drugmaking business and potentially slash prices.
Democrats Winning Key Leadership Jobs Have Taken Millions From Pharma
Top House Republican also received more than $1 million from drugmakers since 2007.
Drugmakers Funnel Millions To Lawmakers; A Few Dozen Get $100,000-Plus
Drugmakers’ contributions to lawmakers have peaked as surging drug prices emerge as a hot-button political issue. In the past decade, Congress has received nearly $79 million from 68 pharma PACs, run by employees of companies that make drugs treating everything from cancer to erectile dysfunction.
